Andreas Diacon1,2, Sachiko Miyahara3, Rodney Dawson2,4, Xin Sun3, Evelyn Hogg5, Kathleen Donahue6, Michael Urbanowski7, Veronique De Jager2, Courtney V Fletcher8, Richard Hafner9, Susan Swindells10, William Bishai7. 1. Division of Physiology, Department of Medical Biochemistry, Stellenbosch University, Cape Town, South Africa. 2. Task Applied Science, Tuberculosis Clinical Research Centre, Bellville, Cape Town, South Africa. 3. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. University of Cape Town Lung Institute and Division of Pulmonology, Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa. 5. Social & Scientific Systems, Inc., Silver Spring, Maryland, USA. 6. Frontier Science & Technology Research Foundation Inc., Amherst, New York, USA. 7. Center for TB Research, Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland. 8. College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska. 9. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 10. Department of Internal Medicine, Division of Infectious Diseases, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Abstract
BACKGROUND: Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial two days of tuberculosis treatment but that isoniazid's activity declines significantly after day three. We conducted a 14-day phase IIa open label, randomized trial to assess the essentiality of isoniazid in standard tuberculosis therapy. METHODS: A total of 69 adults with newly diagnosed sputum-positive tuberculosis from the South African Western Cape region were enrolled and randomized to a four-arm parallel assignment model. Participants were followed for 14 days as inpatients at either the University of Cape Town Lung Institute or at the TASK Applied Science clinical research organization. All arms received standard daily rifampicin, ethambutol, and pyrazinamide but differed as follows: isoniazid only on days one and two (n=17), isoniazid on days one and two then moxifloxacin on days three through 14 (n=16), no isoniazid (n=18), and a control group that received isoniazid for all 14 days (standard therapy, n=18). The primary endpoint was the rate of colony forming unit (CFU) decline during the first 14 days of treatment. RESULTS: For 62 participants analyzed, the initial 14-day mean daily fall in log10 CFU (95% CI) was 0·14 (0·11, 0·18) for participants receiving isoniazid for two days only; 0·13 (0·09, 0·17) for participants receiving isoniazid for two days followed by moxifloxacin; 0·12 (0·08, 0·15) for those not receiving isoniazid; and 0·13 (0·09, 0·16) for the standard therapy group. CONCLUSIONS: The 14 day EBA for the combination rifampicin, ethambutol, and pyrazinamide was not significantly changed by the addition of isoniazid for the first two days or for the first 14 days of treatment. In a post hoc analysis, significantly higher day-two EBAs were observed for all groups among participants with higher baseline sputum CFUs. Our finding that INH does not contribute to EBA suggests that INH could be replaced with another drug during standard treatment to improve efficacy and decrease rates of resistance to first-line drugs. (Funded by the NIH AIDS Clinical Trial Groups and NIH; A5307 ClinicalTrials.gov number, NCT01589497).
BACKGROUND: Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial two days of tuberculosis treatment but that isoniazid's activity declines significantly after day three. We conducted a 14-day phase IIa open label, randomized trial to assess the essentiality of isoniazid in standard tuberculosis therapy. METHODS: A total of 69 adults with newly diagnosed sputum-positive tuberculosis from the South African Western Cape region were enrolled and randomized to a four-arm parallel assignment model. Participants were followed for 14 days as inpatients at either the University of Cape Town Lung Institute or at the TASK Applied Science clinical research organization. All arms received standard daily rifampicin, ethambutol, and pyrazinamide but differed as follows: isoniazid only on days one and two (n=17), isoniazid on days one and two then moxifloxacin on days three through 14 (n=16), no isoniazid (n=18), and a control group that received isoniazid for all 14 days (standard therapy, n=18). The primary endpoint was the rate of colony forming unit (CFU) decline during the first 14 days of treatment. RESULTS: For 62 participants analyzed, the initial 14-day mean daily fall in log10 CFU (95% CI) was 0·14 (0·11, 0·18) for participants receiving isoniazid for two days only; 0·13 (0·09, 0·17) for participants receiving isoniazid for two days followed by moxifloxacin; 0·12 (0·08, 0·15) for those not receiving isoniazid; and 0·13 (0·09, 0·16) for the standard therapy group. CONCLUSIONS: The 14 day EBA for the combination rifampicin, ethambutol, and pyrazinamide was not significantly changed by the addition of isoniazid for the first two days or for the first 14 days of treatment. In a post hoc analysis, significantly higher day-two EBAs were observed for all groups among participants with higher baseline sputum CFUs. Our finding that INH does not contribute to EBA suggests that INH could be replaced with another drug during standard treatment to improve efficacy and decrease rates of resistance to first-line drugs. (Funded by the NIH AIDS Clinical Trial Groups and NIH; A5307 ClinicalTrials.gov number, NCT01589497).
Authors: A H Diacon; J S Maritz; A Venter; P D van Helden; K Andries; D F McNeeley; P R Donald Journal: Eur J Clin Microbiol Infect Dis Date: 2010-09-04 Impact factor: 3.267
Authors: P R Donald; F A Sirgel; F J Botha; H I Seifart; D P Parkin; M L Vandenplas; B W Van de Wal; J S Maritz; D A Mitchison Journal: Am J Respir Crit Care Med Date: 1997-09 Impact factor: 21.405
Authors: Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; Reginah Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron; Kelly E Dooley Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: Simbarashe P Zvada; Paolo Denti; Hennie Geldenhuys; Sandra Meredith; Danelle van As; Mark Hatherill; Willem Hanekom; Lubbe Wiesner; Ulrika S H Simonsson; Amina Jindani; Thomas Harrison; Helen M McIlleron Journal: Antimicrob Agents Chemother Date: 2012-05-14 Impact factor: 5.191
Authors: Emmanuel Chigutsa; Kashyap Patel; Paolo Denti; Marianne Visser; Gary Maartens; Carl M J Kirkpatrick; Helen McIlleron; Mats O Karlsson Journal: Antimicrob Agents Chemother Date: 2012-11-26 Impact factor: 5.191
Authors: Keira A Cohen; Thomas Abeel; Abigail Manson McGuire; Christopher A Desjardins; Vanisha Munsamy; Terrance P Shea; Bruce J Walker; Nonkqubela Bantubani; Deepak V Almeida; Lucia Alvarado; Sinéad B Chapman; Nomonde R Mvelase; Eamon Y Duffy; Michael G Fitzgerald; Pamla Govender; Sharvari Gujja; Susanna Hamilton; Clinton Howarth; Jeffrey D Larimer; Kashmeel Maharaj; Matthew D Pearson; Margaret E Priest; Qiandong Zeng; Nesri Padayatchi; Jacques Grosset; Sarah K Young; Jennifer Wortman; Koleka P Mlisana; Max R O'Donnell; Bruce W Birren; William R Bishai; Alexander S Pym; Ashlee M Earl Journal: PLoS Med Date: 2015-09-29 Impact factor: 11.069
Authors: Prakruti S Rao; Christopher C Moore; Amir A Mbonde; Edwin Nuwagira; Patrick Orikiriza; Dan Nyehangane; Mohammad H Al-Shaer; Charles A Peloquin; Jean Gratz; Suporn Pholwat; Rinah Arinaitwe; Yap Boum; Juliet Mwanga-Amumpaire; Eric R Houpt; Leonid Kagan; Scott K Heysell; Conrad Muzoora Journal: Antibiotics (Basel) Date: 2021-06-18
Authors: David Ekqvist; Anna Bornefall; Daniel Augustinsson; Martina Sönnerbrandt; Michaela Jonsson Nordvall; Mats Fredrikson; Björn Carlsson; Mårten Sandstedt; Ulrika S H Simonsson; Jan-Willem C Alffenaar; Jakob Paues; Katarina Niward Journal: BMJ Open Date: 2022-03-10 Impact factor: 2.692